Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy. The International Initiative on Thrombosis and Cancer is an independent academic working group aimed at establishing a global consensus for the treatment and prophylaxis of VTE in patients with cancer. The International Initiative on Thrombosis and Cancer last updated its evidence-based clinical practice guidelines in 2016 with a free, web-based mobile phone application, which was subsequently endorsed by the International Society on Thrombosis and Haemostasis. The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods, with the support of the French National Cancer Institute. These guidelines were reviewed by an expanded international advisory committee and endorsed by the International Society on Thrombosis and Haemostasis. Results from head-to-head clinical trials that compared direct oral anticoagulant with low-molecular-weight heparin are also summarised, along with new evidence for the treatment and prophylaxis of VTE in patients with cancer.

/pdf/2019-international-clinical-practice-guidelines-for-the-1i79gau8u9.pdf

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

/pdf/2022-esc-guidelines-on-cardio-oncology-developed-in-3fgztpr5.pdf

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

/pdf/2022-esc-guidelines-on-cardio-oncology-developed-in-3nxebqpi.pdf

Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis.

https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14662

Charles Kuzma

Papers

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.

Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial